Biodexa Pharmaceuticals Plc
BDRXHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Biodexa Pharmaceuticals Plc focuses on Biotechnology services and products. Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder. With a market capitalization of $855K, it sits in micro-cap territory. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Market Cap
$854,948
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-67.41
EPS (Fwd)
$0.00
ROE
-64.7%
ROA
-32.8%
Cash
$8.5M
Total Debt
$61,000
Free CF
-$1.0M
52W Change
-97.0%
Annual Financials
Cash vs Debt
Where BDRX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BDRX finished 76.76% below its 150-day moving average ($3.40) and 88.97% below its 200-day moving average ($7.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDRX overbought or oversold?
At the September 3, 2026 close, BDRX's RSI(14) was 1.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $8.5M in cash comfortably exceeding the $61K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$1.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -64.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $699K (2022) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, BDRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Biodexa Pharmaceuticals Plc and its sector.